Free Trial

Mineralys Therapeutics (MLYS) 10K Form and Latest SEC Filings 2026

Mineralys Therapeutics logo
$29.28 -0.37 (-1.25%)
Closing price 04:00 PM Eastern
Extended Trading
$29.29 +0.01 (+0.02%)
As of 05:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest Mineralys Therapeutics SEC Filings & Recent Activity

Mineralys Therapeutics (NASDAQ:MLYS) has submitted 262+ documents to the U.S. Securities and Exchange Commission (SEC) since 2022. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in Mineralys Therapeutics's financial statements. The most recent filing was a Form 4 submitted on April 21, 2026.

Form 4
Mineralys Therapeutics, Inc. Reports Ownership Change on Apr. 21, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Mineralys Therapeutics Files Current Report on Mar. 9, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-K
Mineralys Therapeutics Files Annual Report on Mar. 12, 2026

The 10-K contains Mineralys Therapeutics's audited financial statements, revenue, earnings, and risk factors for the prior fiscal year.

View earnings history

Mineralys Therapeutics SEC Filing History

Browse Mineralys Therapeutics' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
04/21/2026 5:59 PM
Mineralys Therapeutics (1933414) Issuer
Rodman David Malcom (1672659) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/17/2026 3:17 PM
Mineralys Therapeutics (1933414) Subject
Rodman David Malcom (1672659) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/15/2026 8:45 PM
Congleton Jon (1644975) Reporting
Mineralys Therapeutics (1933414) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/15/2026 8:45 PM
Mineralys Therapeutics (1933414) Issuer
Rodman David Malcom (1672659) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/15/2026 3:21 PM
Mineralys Therapeutics (1933414) Subject
Rodman David Malcom (1672659) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/13/2026 8:13 PM
Mineralys Therapeutics (1933414) Issuer
Rodman David Malcom (1672659) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/13/2026 3:18 PM
Mineralys Therapeutics (1933414) Subject
Rodman David Malcom (1672659) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/13/2026 3:22 PM
Congleton Jon (1644975) Reporting
Mineralys Therapeutics (1933414) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/10/2026 3:24 PM
Mineralys Therapeutics (1933414) Filer
Form ARS
04/09/2026 3:24 PM
Mineralys Therapeutics (1933414) Subject
Rodman David Malcom (1672659) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/08/2026 7:47 AM
Mineralys Therapeutics (1933414) Filer
Form DEF 14A
04/08/2026 7:49 AM
Mineralys Therapeutics (1933414) Filer
Form DEFA14A
04/02/2026 5:53 PM
Karydas Daphne (1816952) Reporting
Mineralys Therapeutics (1933414) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/02/2026 5:54 PM
Congleton Jon (1644975) Reporting
Mineralys Therapeutics (1933414) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
03/31/2026 3:15 PM
Congleton Jon (1644975) Reporting
Mineralys Therapeutics (1933414) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/31/2026 3:18 PM
Karydas Daphne (1816952) Reporting
Mineralys Therapeutics (1933414) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/16/2026 4:20 PM
Mineralys Therapeutics (1933414) Issuer
Rodman David Malcom (1672659) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/13/2026 3:50 PM
Mineralys Therapeutics (1933414) Subject
Rodman David Malcom (1672659) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/12/2026 4:19 PM
Mineralys Therapeutics (1933414) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
03/12/2026 3:13 PM
Mineralys Therapeutics (1933414) Subject
Rodman David Malcom (1672659) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/10/2026 4:48 PM
Mineralys Therapeutics (1933414) Issuer
Rodman David Malcom (1672659) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/09/2026 4:15 PM
Mineralys Therapeutics (1933414) Subject
Rodman David Malcom (1672659) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/09/2026 3:36 PM
Mineralys Therapeutics (1933414) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/04/2026 6:25 PM
Mineralys Therapeutics (1933414) Issuer
Warren Eric (1916048) Reporting
Form 3
Initial statement of beneficial ownership of securities  
02/20/2026 6:46 PM
Levy Adam Scott (1693134) Reporting
Mineralys Therapeutics (1933414) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/20/2026 6:46 PM
Mineralys Therapeutics (1933414) Issuer
Rodman David Malcom (1672659) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/20/2026 6:47 PM
DiRocco Derek (1792061) Reporting
Mineralys Therapeutics (1933414) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/20/2026 6:47 PM
AKKARAJU SRINIVAS (1253170) Reporting
Mineralys Therapeutics (1933414) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/20/2026 6:47 PM
Mineralys Therapeutics (1933414) Issuer
Slingsby Brian Taylor (1963901) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/20/2026 6:47 PM
Karydas Daphne (1816952) Reporting
Mineralys Therapeutics (1933414) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/20/2026 6:47 PM
Gold Alexander M (2026429) Reporting
Mineralys Therapeutics (1933414) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/20/2026 6:47 PM
Mineralys Therapeutics (1933414) Issuer
SBLENDORIO GLENN (1277478) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/20/2026 6:47 PM
Congleton Jon (1644975) Reporting
Mineralys Therapeutics (1933414) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/20/2026 6:49 PM
Kolchinsky Peter (1384859) Reporting
Mineralys Therapeutics (1933414) Issuer
RA Capital Healthcare Fund LP (1315082) Reporting
RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting
RA Capital Nexus Fund III, L.P. (1883840) Reporting
Shah Rajeev M. (1619841) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/17/2026 5:56 PM
Mineralys Therapeutics (1933414) Issuer
Rodman David Malcom (1672659) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/13/2026 6:25 PM
Mineralys Therapeutics (1933414) Issuer
Rodman David Malcom (1672659) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/13/2026 3:30 PM
Catalys Pacific Fund, LP (1746274) Filed by
Mineralys Therapeutics (1933414) Subject
Form SCHEDULE 13G/A
02/13/2026 8:21 AM
Mineralys Therapeutics (1933414) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
02/11/2026 5:58 PM
Mineralys Therapeutics (1933414) Issuer
Rodman David Malcom (1672659) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/09/2026 3:20 PM
Mineralys Therapeutics (1933414) Subject
Rodman David Malcom (1672659) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/05/2026 12:31 PM
Mineralys Therapeutics (1933414) Subject
Form SCHEDULE 13G
01/21/2026 11:30 AM
BlackRock, Inc. (2012383) Filed by
Mineralys Therapeutics (1933414) Subject
Form SCHEDULE 13G
01/20/2026 7:33 PM
Mineralys Therapeutics (1933414) Issuer
Rodman David Malcom (1672659) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/20/2026 3:26 PM
Mineralys Therapeutics (1933414) Subject
Rodman David Malcom (1672659) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/15/2026 6:07 PM
Mineralys Therapeutics (1933414) Issuer
Rodman David Malcom (1672659) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/14/2026 3:00 PM
Mineralys Therapeutics (1933414) Subject
Rodman David Malcom (1672659) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/13/2026 7:43 PM
Mineralys Therapeutics (1933414) Issuer
Rodman David Malcom (1672659) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/13/2026 7:43 PM
Levy Adam Scott (1693134) Reporting
Mineralys Therapeutics (1933414) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/13/2026 7:43 PM
Congleton Jon (1644975) Reporting
Mineralys Therapeutics (1933414) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/13/2026 3:10 PM
Mineralys Therapeutics (1933414) Subject
Rodman David Malcom (1672659) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/12/2026 3:23 PM
Congleton Jon (1644975) Reporting
Mineralys Therapeutics (1933414) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/12/2026 3:23 PM
Levy Adam Scott (1693134) Reporting
Mineralys Therapeutics (1933414) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/12/2026 3:24 PM
Mineralys Therapeutics (1933414) Subject
Rodman David Malcom (1672659) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/09/2026 3:23 PM
Mineralys Therapeutics (1933414) Subject
Rodman David Malcom (1672659) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/06/2026 6:20 PM
Mineralys Therapeutics (1933414) Issuer
Rodman David Malcom (1672659) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/06/2026 7:05 AM
Mineralys Therapeutics (1933414) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/02/2026 4:18 PM
Mineralys Therapeutics (1933414) Subject
Rodman David Malcom (1672659) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/24/2025 4:07 PM
Congleton Jon (1644975) Reporting
Mineralys Therapeutics (1933414) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/21/2025 5:07 PM
Catalys Pacific Fund, LP (1746274) Reporting
Mineralys Therapeutics (1933414) Issuer
Slingsby Brian Taylor (1963901) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/20/2025 4:19 PM
Catalys Pacific Fund, LP (1746274) Reporting
Mineralys Therapeutics (1933414) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/13/2025 6:01 PM
Gold Alexander M (2026429) Reporting
Mineralys Therapeutics (1933414) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/13/2025 6:01 PM
Karydas Daphne (1816952) Reporting
Mineralys Therapeutics (1933414) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/13/2025 6:01 PM
Congleton Jon (1644975) Reporting
Mineralys Therapeutics (1933414) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/13/2025 6:01 PM
Levy Adam Scott (1693134) Reporting
Mineralys Therapeutics (1933414) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
11/13/2025 3:03 PM
Gold Alexander M (2026429) Reporting
Mineralys Therapeutics (1933414) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/13/2025 3:04 PM
Karydas Daphne (1816952) Reporting
Mineralys Therapeutics (1933414) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/12/2025 3:28 PM
Congleton Jon (1644975) Reporting
Mineralys Therapeutics (1933414) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/12/2025 3:32 PM
Levy Adam Scott (1693134) Reporting
Mineralys Therapeutics (1933414) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/10/2025 4:25 PM
Mineralys Therapeutics (1933414) Filer
Form S-3ASR
11/10/2025 4:11 PM
Mineralys Therapeutics (1933414) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
10/15/2025 6:04 PM
Mineralys Therapeutics (1933414) Issuer
Rodman David Malcom (1672659) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/15/2025 6:04 PM
Congleton Jon (1644975) Reporting
Mineralys Therapeutics (1933414) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/15/2025 6:04 PM
Levy Adam Scott (1693134) Reporting
Mineralys Therapeutics (1933414) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/15/2025 3:09 PM
Mineralys Therapeutics (1933414) Subject
Rodman David Malcom (1672659) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/14/2025 9:09 AM
Congleton Jon (1644975) Reporting
Mineralys Therapeutics (1933414) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
10/14/2025 9:13 AM
Levy Adam Scott (1693134) Reporting
Mineralys Therapeutics (1933414) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/16/2025 5:54 PM
Mineralys Therapeutics (1933414) Issuer
Rodman David Malcom (1672659) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/15/2025 3:12 PM
Mineralys Therapeutics (1933414) Subject
Rodman David Malcom (1672659) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
09/08/2025 7:05 PM
Mineralys Therapeutics (1933414) Subject
Samsara BioCapital, L.P. (1699737) Filed by
Form SCHEDULE 13D/A
09/08/2025 7:07 PM
AKKARAJU SRINIVAS (1253170) Reporting
Mineralys Therapeutics (1933414) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
09/08/2025 4:59 PM
Kolchinsky Peter (1384859) Reporting
Mineralys Therapeutics (1933414) Issuer
RA Capital Healthcare Fund LP (1315082) Reporting
RA CAPITAL MANAGEMENT, L.P. (1346824) Reporting
RA Capital Nexus Fund III, L.P. (1883840) Reporting
Shah Rajeev M. (1619841) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
09/08/2025 5:00 PM
Mineralys Therapeutics (1933414) Subject
RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by
Form SCHEDULE 13D/A
09/02/2025 7:51 PM
Mineralys Therapeutics (1933414) Filer
Form S-3MEF
08/14/2025 5:02 PM
Mineralys Therapeutics (1933414) Issuer
Rodman David Malcom (1672659) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/13/2025 4:21 PM
Mineralys Therapeutics (1933414) Subject
Rodman David Malcom (1672659) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/12/2025 4:20 PM
Mineralys Therapeutics (1933414) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
07/30/2025 7:12 PM
Levy Adam Scott (1693134) Reporting
Mineralys Therapeutics (1933414) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
07/30/2025 4:30 PM
Levy Adam Scott (1693134) Reporting
Mineralys Therapeutics (1933414) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/30/2025 8:29 AM
Levy Adam Scott (1693134) Reporting
Mineralys Therapeutics (1933414) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/28/2025 4:38 PM
Levy Adam Scott (1693134) Reporting
Mineralys Therapeutics (1933414) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/15/2025 4:00 PM
Mineralys Therapeutics (1933414) Issuer
Rodman David Malcom (1672659) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
07/15/2025 4:01 PM
Levy Adam Scott (1693134) Reporting
Mineralys Therapeutics (1933414) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
07/15/2025 4:02 PM
Congleton Jon (1644975) Reporting
Mineralys Therapeutics (1933414) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
07/14/2025 3:23 PM
Mineralys Therapeutics (1933414) Subject
Rodman David Malcom (1672659) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/11/2025 3:10 PM
Levy Adam Scott (1693134) Reporting
Mineralys Therapeutics (1933414) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/11/2025 3:11 PM
Congleton Jon (1644975) Reporting
Mineralys Therapeutics (1933414) Subject
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/17/2025 6:07 AM
Mineralys Therapeutics (1933414) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/13/2025 3:23 PM
Mineralys Therapeutics (1933414) Subject
Rodman David Malcom (1672659) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/15/2025 6:01 PM
Mineralys Therapeutics (1933414) Issuer
Rodman David Malcom (1672659) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/13/2025 7:57 PM
Mineralys Therapeutics (1933414) Issuer
Rodman David Malcom (1672659) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
(Data available from 1/1/2016 forward)

Mineralys Therapeutics SEC Filings - Frequently Asked Questions

Mineralys Therapeutics (MLYS) has submitted 262+ filings to the SEC since 2022. You can browse the complete history or filter by form type using the tools above.

Mineralys Therapeutics's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on Mineralys Therapeutics's financial statements page.

The most recent filing was a Form 4 submitted on April 21, 2026. This was an insider ownership change filed by 4 - Mineralys Therapeutics, Inc. (0001933414) (Issuer).

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:MLYS) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners